Presage Biosciences Announces New Pharma Partnership With AstraZeneca To Evaluate Novel Immuno-Oncology Drug Combinations With CIVO Technology
Portfolio Pulse from Benzinga Newsdesk
Presage Biosciences has partnered with AstraZeneca to use its CIVO technology for evaluating novel immuno-oncology drug combinations in head and neck cancer patients. This collaboration aims to advance AstraZeneca's portfolio of immuno-oncology agents. Earlier, Presage presented a study at SITC 2023 showing the effectiveness of CIVO in analyzing Merck's KEYTRUDA in patient tumors, highlighting the limitations of animal studies compared to the intact tumor microenvironment.
November 30, 2023 | 1:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AstraZeneca partners with Presage Biosciences to use CIVO technology for evaluating immuno-oncology drug combinations, potentially enhancing its cancer treatment portfolio.
The partnership with Presage Biosciences is likely to be viewed positively as it could lead to advancements in AstraZeneca's immuno-oncology portfolio. The use of CIVO technology may accelerate the development of effective cancer treatments, potentially improving AstraZeneca's market position in oncology.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80